

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**HOLDING ANNOUNCEMENT**  
**TRADING HALT**

Reference is made to the trading halt announcement of Aceso Life Science Group Limited (the “**Company**”) dated 4 October 2024 and the Company wishes to provide the following update to shareholders and potential investors.

As disclosed in the said announcement, trading in the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) has been halted with effect from 9:00 a.m. on Friday, 4 October 2024, pending the release of an announcement in relation to a notifiable transaction of the Company.

The transaction involves a placing of new shares by Hao Tian International Construction Investment Group Limited (stock code: 1341) (“**HTICI**”), a non wholly-owned subsidiary of the Company. On 3 October 2024, HTICI has announced that it has entered into a placing agreement for placing of new shares under specific mandate (the “**HTICI Placing**”). For details, please refer to the announcement of HTICI dated 3 October 2024. The HTICI Placing will result in dilution of shareholding interest in HTICI of the Company which constitutes a deemed disposal transaction of the Company (the “**Possible Deemed Disposal**”). The Possible Deemed Disposal, if materializes, will constitute a very substantial disposal of the Company (the “**VSD**”) under Chapter 14 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

The announcement of the Company on VSD (the “**VSD Announcement**”) is subject to review by the Stock Exchange pursuant to Rule 13.52(2) of the Listing Rules before it is issued. As at the date of this announcement, the Company is in the process of preparing and addressing the enquiries raised by the Stock Exchange on the VSD Announcement. The VSD Announcement will be published in accordance with the Listing Rules as soon as practicable.

Trading in the shares of the Company will remain halted pending publication of the VSD Announcement.

By order of the Board  
**Aceso Life Science Group Limited**  
**Fok Chi Tak**  
*Executive Director*

Hong Kong, 14 October 2024

*As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.*